Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Navitoclax + Chemotherapy in R/R ALL/LL
NCT03181126Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2017
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of venetoclax and navitoclax in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by AbbVie Inc. Primary endpoints: Maximum Plasma Concentration up to 9 months, Area Under the Curve up to 9 months and 3 more. Started Nov 2017; status: completed.
02
Drugs
venetoclaxnavitoclax
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT03181126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03181126.